Technical Data
M2412-50F
Maspin (Serpin peptidase inhibitor, clade B (ovalbumin), member 5, Peptidase inhibitor 5, PI5, PI-5, Serpin B5)
Description:
Serine (or cysteine) proteinase inhibitor clade B (ovalbumin) member 5, also known as Maspin, is a tumor suppressor protein of serine proteinase inhibitor family. It plays an essential role in embryonic development through critical roles in cell adhesion. Also, it is present in normal breast and prostatic epithelial cells but downregulated in the respective carcinomas.

Applications:
Suitable for use in Immunofluorescence, ELISA and Western Blot. Other applications not tested.

Recommended Dilutions:
Immunofluorescence: 1:500 detects Maspin in human HeLa cells
Western Blot: 1:1000-1:2000. Cell lysates of HeLa cells (20ug) were resolved by SDS-PAGE, transferred to NC membrane and probed with M21412-50F (1:1000). Proteins were visualized using a goat anti-mouse secondary antibody conjugated to HRP* and an ECL detection system.
Optimal dilutions to be determined by researcher.

*Recommended Secondary Antibodies:
I1904-06C: IgG, H&L (HRP) (X-Adsorbed) Pab Gt xMo
I1904-06H: IgG, H&L (HRP) (X-Adsorbed) Pab Gt xMo

Hybridoma:
Mouse F0 myeloma cells with spleen cells from BALB/c mice.

Storage and Stability:
May be stored at 4C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20C. Aliquots are stable for 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
TypeIsotypeCloneGrade
MabIgG2b,k10K402Purified
SizeStorageShippingSourceHost
100ul-20CBlue IceHumanMouse
Concentration:
~1mg/ml
Immunogen:
Recombinant corresponding to aa1-375 from human Maspin purified from E. coli (NP_002630).
Purity:
Purified by Protein G affinity chromatography.
Form
Supplied as a liquid in PBS, pH 7.4, 0.1% sodium azide.
Specificity:
Recognizes human Maspin.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
1. Lockett J. et al., (2006) J Cell Biochem 97(4):651-660 2. Khalkhali Ellis Z. et al., (2006) Clin Cancer Res 12(24):7279-7283.